ワクチンアジュバント市場：動向、機会および競合分析（2023年～2028年）

世界のワクチンアジュバントの市場規模は、2023年～2028年にかけて12.6.%のCAGRで拡大し、2028年までに26億米ドルに達すると予測されています。この市場の主な促進要因は、感染症の有病率の上昇、ワクチン研究開発に対する政府の取り組みと資金の増加です。

当レポートでは、世界のワクチンアジュバント市場について調査し、市場の概要とともに、製品別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界のワクチンアジュバント市場：市場力学

第3章 市場動向と予測分析、2017年～2028年

• マクロ経済の動向（2017年～2022年）と予測（2023年～2028年）
• 世界のワクチンアジュバント市場の動向（2017年～2022年）と予測（2023年～2028年）
• 世界のワクチンアジュバント市場、製品別
  • 病原体
  • アジュバントエマルジョン
  • 微粒子
  • 併用
• 世界のワクチンアジュバント市場、用途別
  • 感染症
  • 癌

第4章 市場動向と予測分析、地域別、2017年～2028年

• 世界のワクチンアジュバント市場、地域別
• 北米のワクチンアジュバント市場
• 欧州のワクチンアジュバント市場
• アジア太平洋のワクチンアジュバント市場
• その他の地域のワクチンアジュバント市場

第5章 競合の分析

第6章 成長機会と戦略分析

• 成長機会分析
• 戦略分析

第7章 主要参入企業の企業プロファイル

• GlaxoSmithKline
• Novavax
• SPI Pharma
• Agenus
• CSL Limited
• InvivoGen
• Brenntag Biosector

Vaccine Adjuvant Market Trends and Forecast

The future of the vaccine adjuvant market looks promising with opportunities in infectious disease and cancer applications. The global vaccine adjuvant market is expected to reach an estimated $2.6 billion by 2028 with a CAGR of 12.6.% from 2023 to 2028. The major drivers for this market are increasing prevalence of infectious diseases and increasing government initiatives and funding for vaccine research and development.

Vaccine Adjuvant Market by Product, Application, and Region

A more than 150-page report is developed to help in your business decisions. A sample figure with some insights is shown below.

Vaccine Adjuvant Market by Segments

Vaccine Adjuvant Market by Segment

The study includes trends and forecast for the global vaccine adjuvant market by product, application, and region, as follows:

Vaccine Adjuvant Market by Product [Value ($B) Shipment Analysis from 2017 to 2028]:

Pathogen

Adjuvant Emulsion

Particulate

Combination

Vaccine Adjuvant Market by Application [Value ($B) Shipment Analysis from 2017 to 2028]:

Infectious Diseases

Cancer

Vaccine Adjuvant Market by Region [Value ($B) Shipment Analysis from 2017 to 2028]:

North America

Europe

Asia Pacific

The Rest of the World

List of Vaccine Adjuvants Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, vaccine adjuvant companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the vaccine adjuvant companies profiled in this report include-

GlaxoSmithKline

Novavax

SPI Pharma

Agenus

CSL Limited

InvivoGen

Brenntag Biosector

Vaccine Adjuvant Market Insights

Lucintel forecast that adjuvant emulsion will remain the largest product segment over the forecast period due to growing number of adjuvanted vaccines across the globe.

Infectious disease segment is projected to witness the highest growth due to growing prevalence of infectious diseases, such as malaria, influenza, and hepatitis A, B, & C and increasing government initiatives to support vaccine development.

The North American region is expected to witness the highest growth during the forecast period due to increasing investment for the development of veterinary healthcare infrastructure and growing government initiatives towards immunization programs.

Features of the Vaccine Adjuvant Market

Market Size Estimates: Vaccine adjuvant market size estimation in terms of value ($B)

Trend And Forecast Analysis: Market trends (2017-2022) and forecast (2023-2028) by various segments and regions.

Segmentation Analysis: Vaccine adjuvant market size by various segments, such as by product, application, and region

Regional Analysis: Vaccine adjuvant market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.

Growth Opportunities: Analysis on growth opportunities in different products, applications, and regions for the vaccine adjuvant market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape for the vaccine adjuvant market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the vaccine adjuvant market size?

Answer: The global vaccine adjuvant market is expected to reach an estimated $2.6 billion by 2028.

Q2. What is the growth forecast for vaccine adjuvant market?

Answer: The global vaccine adjuvant market is expected to grow with a CAGR of 12.6% from 2023 to 2028.

Q3. What are the major drivers influencing the growth of the vaccine adjuvant market?

Answer: The major drivers for this market are increasing prevalence of infectious diseases and increasing government initiatives and funding for vaccine research and development.

Q4. What are the major segments for vaccine adjuvant market?

Answer: The future of the vaccine adjuvant market looks promising with opportunities in infectious disease and cancer applications.

Q5. Who are the key vaccine adjuvant companies?

Answer: Some of the key vaccine adjuvant companies are as follows:

GlaxoSmithKline

Novavax

SPI Pharma

Agenus

CSL Limited

InvivoGen

Brenntag Biosector

Q6. Which vaccine adjuvants segment will be the largest in the future?

Answer: Lucintel forecast that adjuvant emulsion will remain the largest product segment over the forecast period due to growing number of adjuvanted vaccines across the globe.

Q7. In vaccine adjuvant market, which region is expected to be the largest in next 5 years?

Answer: The North American region is expected to witness the highest growth during the forecast period due to increasing investment for the development of veterinary healthcare infrastructure and growing government initiatives towards immunization programs.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% Customization Without any Additional Cost.

This report answers following 11 key questions

• Q.1. What are some of the most promising, high-growth opportunities for the vaccine adjuvant market by product (pathogen, adjuvant emulsion, particulate, and combination), application (infectious diseases and cancer), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last five years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Vaccine Adjuvant Market: Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2017 to 2028

• 3.1: Macroeconomic Trends (2017-2022) and Forecast (2023-2028)
• 3.2: Global Vaccine Adjuvant Market Trends (2017-2022) and Forecast (2023-2028)
• 3.3: Global Vaccine Adjuvant Market by Product
  • 3.3.1: Pathogen
  • 3.3.2: Adjuvant Emulsion
  • 3.3.3: Particulate
  • 3.3.4: Combination
• 3.4: Global Vaccine Adjuvant Market by Application
  • 3.4.1: Infectious Diseases
  • 3.4.2: Cancer

4. Market Trends and Forecast Analysis by Region from 2017 to 2028

• 4.1: Global Vaccine Adjuvant Market by Region
• 4.2: North American Vaccine Adjuvant Market
  • 4.2.1: North American Vaccine Adjuvant Market by Product: Pathogen, Adjuvant Emulsion, Particulate, and Combination
  • 4.2.2: North American Vaccine Adjuvant Market by Application: Infectious Diseases and Cancer
• 4.3: European Vaccine Adjuvant Market
  • 4.3.1: European Vaccine Adjuvant Market by Product: Pathogen, Adjuvant Emulsion, Particulate, and Combination
  • 4.3.2: European Vaccine Adjuvant Market by Application: Infectious Diseases and Cancer
• 4.4: APAC Vaccine Adjuvant Market
  • 4.4.1: APAC Vaccine Adjuvant Market by Product: Pathogen, Adjuvant Emulsion, Particulate, and Combination
  • 4.4.2: APAC Vaccine Adjuvant Market by Application: Infectious Diseases and Cancer
• 4.5: ROW Vaccine Adjuvant Market
  • 4.5.1: ROW Vaccine Adjuvant Market by Product: Pathogen, Adjuvant Emulsion, Particulate, and Combination
  • 4.5.2: ROW Vaccine Adjuvant Market by Application: Infectious Diseases and Cancer

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Vaccine Adjuvant Market by Product
  • 6.1.2: Growth Opportunities for the Global Vaccine Adjuvant Market by Application
  • 6.1.5: Growth Opportunities for the Global Vaccine Adjuvant Market by Region
• 6.2: Strategic Analysis
  • 6.2.1: New Product Development
  • 6.2.2: Capacity Expansion of the Global Vaccine Adjuvant Market
  • 6.2.3: Mergers, Acquisitions, and Joint Ventures in the Global Vaccine Adjuvant Market
  • 6.2.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: Novavax
• 7.3: SPI Pharma
• 7.4: Agenus
• 7.5: CSL Limited
• 7.6: InvivoGen
• 7.7: Brenntag Biosector